Galderma Group N (GALD) - Total Assets
Based on the latest financial reports, Galderma Group N (GALD) holds total assets worth CHF12.88 Billion CHF (≈ $16.28 Billion USD) as of June 2025. Total assets represent everything the company owns and controls, combining both current assets—like cash and cash equivalents, accounts receivable, and inventories—and non-current assets such as property, plant, equipment (PP&E), intangible assets, and long-term investments.
Galderma Group N - Total Assets Trend (2021–2024)
This chart illustrates how Galderma Group N's total assets have evolved over time, based on quarterly financial data. Also see GALD company net worth for the company's overall valuation and market capitalisation.
Galderma Group N - Asset Composition Analysis
Current Asset Composition (December 2024)
Galderma Group N's total assets of CHF12.88 Billion consist of 14.6% current assets and 85.4% non-current assets. Review Galderma Group N (GALD) total liabilities to assess the company's total debt and financial obligations.
| Asset Category | Amount (CHF) | % of Total Assets |
|---|---|---|
| Cash & Equivalents | CHF175.00 Million | 3.6% |
| Accounts Receivable | CHF910.00 Million | 7.2% |
| Inventory | CHF403.00 Million | 3.2% |
| Property, Plant & Equipment | CHF577.00 Million | 4.6% |
| Intangible Assets | CHF4.83 Billion | 38.3% |
| Goodwill | CHF5.13 Billion | 40.7% |
Asset Composition Trend (2021–2024)
This chart illustrates how Galderma Group N's asset composition has evolved over time. Understanding changes in asset allocation can provide insights into the company's strategic shifts, capital allocation priorities, and business focus evolution. See latest Galderma Group N stock price today for real-time trading data and today's change.
Key Asset Composition Facts
- Current vs. Non-Current Assets: Galderma Group N's current assets represent 14.6% of total assets in 2024, an increase from 12.1% in 2021.
- Cash Position: Cash and equivalents constituted 3.6% of total assets in 2024, up from 2.3% in 2021.
- Tangible vs. Intangible: Intangible assets (including goodwill) make up 78.0% of total assets, a decrease from 82.0% in 2021.
- Asset Diversification: The largest asset category is goodwill at 40.7% of total assets.
Galderma Group N Competitors by Total Assets
Key competitors of Galderma Group N based on total assets are shown below.
| Company | Country | Total Assets |
|---|---|---|
|
Swedish Orphan Biovitrum AB (publ)
ST:SOBI
|
Sweden | Skr81.26 Billion |
|
Jiangsu Hengrui Medicine Co Ltd
SHG:600276
|
China | CN¥68.33 Billion |
|
Yunnan Baiyao Group Co Ltd
SHE:000538
|
China | CN¥53.34 Billion |
|
Richter Gedeon Vegyészeti Gyár Nyilvánosan Muködo Rt
F:RIG2
|
Germany | €1.60 Trillion |
|
Beijing Tongrentang Co Ltd
SHG:600085
|
China | CN¥29.95 Billion |
|
Hubei Jumpcan Pharmaceutical Co Ltd
SHG:600566
|
China | CN¥17.01 Billion |
|
Shijiazhuang Yiling Pharmaceutical Co Ltd
SHE:002603
|
China | CN¥13.98 Billion |
|
ASPEN PHAR.UN.ADR /1 O.N.
F:LDZU
|
Germany | €128.04 Billion |
Galderma Group N - Liquidity and Working Capital Analysis
Liquidity ratios measure a company's ability to pay off its short-term debts as they come due, using the company's current or quick assets. Working capital represents the operational liquidity available.
Key Liquidity Metrics
| Metric | Current | 1 Year Ago | 5 Years Ago |
|---|---|---|---|
| Current Ratio | 1.09 | 1.20 | 1.03 |
| Quick Ratio | 0.80 | 0.92 | 0.76 |
| Cash Ratio | 0.26 | 0.29 | 0.00 |
| Working Capital | CHF160.00 Million | CHF265.01 Million | CHF38.38 Million |
Galderma Group N - Advanced Valuation Insights
This section examines the relationship between Galderma Group N's asset base and its market valuation, helping to identify whether the company's assets are efficiently translated into market value.
Key Valuation Metrics
| Current Price-to-Book Ratio | 6.11 |
| Latest Market Cap to Assets Ratio | 2.93 |
| Asset Growth Rate (YoY) | 20.3% |
| Total Assets | CHF12.62 Billion |
| Market Capitalization | $37.01 Billion USD |
Valuation Analysis
Premium Asset Valuation: The market values Galderma Group N's assets at a significant premium (2.93x), suggesting investors see substantial growth potential or unique competitive advantages.
Rapid Asset Growth: Galderma Group N's assets grew by 20.3% over the past year, indicating significant expansion of the company's resource base.
Annual Total Assets for Galderma Group N (2021–2024)
The table below shows the annual total assets of Galderma Group N from 2021 to 2024.
| Year | Total Assets | Change |
|---|---|---|
| 2024-12-31 | CHF12.62 Billion ≈ $15.95 Billion |
+20.28% |
| 2023-12-31 | CHF10.49 Billion ≈ $13.26 Billion |
-8.68% |
| 2022-12-31 | CHF11.49 Billion ≈ $14.52 Billion |
+0.27% |
| 2021-12-31 | CHF11.45 Billion ≈ $14.48 Billion |
-- |
About Galderma Group N
Galderma Group AG operates as a dermatology company worldwide. The company delivers a science-based portfolio of brands and services for the dermatology market, including injectable aesthetics, dermatological skincare, and therapeutic dermatology. Its portfolio of flagship brands includes Azzalure, ALLUZIENCE, Dysport, Restylane, Restylane Skinboosters, Sculptra, Cetaphil, ALASTIN, Soolantra, Epi… Read more